|Ms. Jill C. Milne||Co-Founder, CEO, Pres & Director||827.08k||N/A||1968|
|Dr. Andrew J. Nichols||Chief Scientific Officer||557.71k||N/A||1961|
|Dr. Joanne M. Donovan||Chief Medical Officer & Sr. VP of Clinical Devel.||669.52k||N/A||1957|
|Mr. Noah Clauser||VP of Fin. & Controller||N/A||N/A||N/A|
|Ms. Deirdre A. Cunnane||Chief Legal Officer & Treasurer||N/A||N/A||1965|
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Catabasis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.